HN - HPV and Head & Neck Forum
April 11-12, 2022 • Room 16a
Coordinators: J. P. Klussmann (Germany) - K. A. Lang Kuhs (USA) - E. Rettig (USA)
The EUROGIN HPV and Head & Neck Cancer Forum highlights recent advances and areas of active research in the field of HPV-related head and neck cancers. This year’s Forum features the emerging role of biomarkers in screening and management of HPV-related oropharyngeal cancer, updates epidemiological data, emphasizes survivorship and surveillance, highlights deintensification trials and other therapeutic innovations, and a dedicated session focusing on molecular & immunologic considerations.
Monday, April 11
HN 01
Screening, prevention and epidemiology
Chair: K. A. Lang Kuhs (USA) - T. Waterboer (Germany)
14.00 - 15.30
HN 01-1
Introduction
Lang Kuhs K. A. (USA)
Waterboer T. (Germany)
HN 01-2
HPV in oropharynx and non-oropharynx
D’Souza A. (USA)
HN 01-3
Updates in epidemiologic trends - oral HPV infection& HPV-OPC
Alemany L. (Spain)
Video presentation
HN 01-4
Vaccination trials
Giuliano A. (USA)
HN 01-5
Absolute risk of oropharyngeal cancer after an HPV16-E6 serology test and implications for screening
Robbins H. (France)
HN 01-6
Screening for HPV-OPC:Overview of screening concepts
Waterboer T. (Germany)
HN 01-7
Screening trial updates
Sturgis E. (USA)
Discussion
Coffee Break
15.30 - 16.00
HN 02
Screening, prevention and epidemiology
Chair: K. A. Lang Kuhs (USA) - T. Waterboer (Germany)
16.00 - 17.30
HN 02-1
Introduction
Rettig E. (USA)
HN 02-2
ctHPVDNA for Surveillance of HPV-positive Oropharynx Cancer
Chera B. S. (USA)
Video presentation
HN 02-3
Patient concerns, priorities & decision-making
Windon M. (USA)
HN 02-4
Swallowing evaluation, interventions, and outcomes
Starmer H. (USA)
HN 02-5
The psychology of surviving a sex/STI-linked cancer like HPV-associated cancer
Osazuwa-Peters N. (USA)
HN 02-6
HNC survivorship
Murphy B. (USA)
Video presentation
Discussion
HN 03
Management / Clinical trials
Chair: J. P. Klussmann (Germany)
17.30 - 19.00
HN 03-1
Introduction
Klussmann J. P. (Germany)
HN 03-2
Radiation reduction in human papillomavirus related oropharyngeal cancer
Lee N. Y. (USA)
Video presentation
HN 03-3
Deintensification of adjuvant radiation after surgery for HPV+ OPC
Ma D. (USA)
Video presentation
HN 03-4
Management of incurable disease or clinical trials for incurable disease
Massarelli E. (USA)
Video presentation
HN 03-5
Work-up of unknown primary
Holsinger C. (USA)
Video presentation
HN 03-6
Neoadjuvant immunotherapy
Mirghani H. (France)
Discussion
Tuesday, April 12
HN 04
Submitted papers
Chair: T. Dalianis (Sweden)
8.00 - 9.30
HN 04-1
Prevalence and incidence of oral-HPV among people living with HIV: what do we know?
Mandishora R. (USA)
HN 04-2
Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positivehead and neck cancer
Rettig E. (USA)
HN 04-3
Experimental studies with combinations of targeted therapy on HPV positive and negative tonsillar and base of tongue cancer lines reveals synergistic effects
Holzhauser S. (Sweden)
HN 04-4
Promising epigenetic biomarker for improved detection of head and neck cancer in non-invasive specimen
Hoyer C. (Germany)
HN 04-5
Whole exome sequencing of HPV positive tonsillar and base of tongue squamous cell carcinomas reveals a global mutational pattern along with relapse-specific somatic variants
Dalianis T. (Sweden)
HN 04-6
Attributable fraction of HPV in advanced stage head and neck cancers per geographical region: results from a systematic literature review – the ‘ALARM’ study
Athanaopoulos C. (Greece)
HN 04-7
HPV related oropharyngeal cancer : a noninstitutional experience of upfront mini-invasive transoral surgery (TOS) versus curative chemoradiation
Zorzi S. F. (Italy)
HN 04-8
Assessing the burden of HPV-related head and neck cancers in mainland China: the designof BROADEN-China study
Qiao Y. L. (China)
HN 05
Carcinogenesis & molecular characterization
Chair: S. Virani (France)
13.15 - 14.45
HN 05-1
Introduction
Virani S. (France)
HN 05-2
Deep learning
Klein S. (Germany)
HN 05-3
Single cell sequencing
Puram S. (USA)
HN 05-4
Liquid Biopsy
Faden D. (USA)
HN 05-5
Pathology
Lewis J. (USA)
HN 05-6
Characterization of the HPV genome in the Voyager Consortium
Virani S. (France)
HN 05-7
HPV16 genetic variation and prognosis
Lang Kuhs K. A. (USA)
Discussion
Coffee Break
14.45 - 15.15
HN 06
Immunologic considerations
Chair: S. Van der Burg (Netherlands)
15.15 - 16.45
HN 06-1
Introduction
Van der Burg S. (Netherlands)
HN 06-2
Immunologic landscape in HPV+ vs HPV- HNSCC
Sikora A. G. (USA)
Video presentation
HN 06-3
HPV-specific T cell response
Van der Burg S. (Netherlands)
HN 06-4
Enhancing immune response to HPV-OPC: tumor vaccines, CAR-T therapy
Massarelli E. (USA)
Video presentation
HN 06-5
Defining HPV-specific B cell responses in patients with head and neck cancer
Wieland A. (USA)
HN 06-6
Role of immunotherapy in HPV-OPC
Hanna G. J. (USA)
Video presentation
Discussion
EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists whose work is related to genital infections and neoplasia.
EUROVIR, owning the trademark EUROGIN, is a Trusted Partner of Ethical MedTech.